{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:45:19Z","timestamp":1774579519047,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>S\u00e9zary syndrome (SS) is a leukemic form of cutaneous T cell lymphoma (CTCL), distinguished from mycosis fungoides by the presence of cancerous lymphocytes in the blood and often bears very poor prognoses. SS treatment is palliative, and thus novel therapies are needed. The CD7 surface antigen is highly expressed and confined to the surface of T cells, therefore when present, serves as a promising target for immunotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Herein we describe the preclinical validation and clinical application of our non-gene editing CD7 targeted chimeric antigen receptor (CAR) T therapy to treat relapsed\/refractory (r\/r) CD7 expressing SS. The CD7 CAR construct possesses a \u201csafety switch\u201d (RTX) to enable rapid depletion of the CAR T treatment with administration of rituximab. Preclinical evaluation of the CD7-RTX CAR T cells demonstrated &amp;gt;99% depletion of target cells in both co-cultures, at 1:1 and 2:1 effector: target (E:T) ratios, and mouse models. In a mouse model, \u201csafety switch\u201d testing resulted in rapid elimination of CAR T cells with rituximab infusion. RTX, in our CD7 therapy, has not yet been clinically validated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A 53-year-old male diagnosed with r\/r SS, expressing CD7, was treated with 2\u00d710<jats:sup>6<\/jats:sup> CD7-RTX CAR T cells\/kg of body weight, as compassionate use. The patient achieved medication and symptom free complete remission (CR) within 28 days post-CAR. The patient remained in CR at 18-month follow-up. The treatment was well tolerated and without severe adverse events (SAEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our CD7-RTX CAR T therapy demonstrates exceptional safety and efficacy in one patient with CD7<jats:sup>+<\/jats:sup> r\/r SS. This was the first recorded use of CD7 targeted CAR T therapy to treat SS. SS is prototypically CD7<jats:sup>-<\/jats:sup>, thus despite its efficacy in this patient, this treatment approach is likely not generalizable to most SS patients. However, this study supports the importance of thorough tumor characterization and the potential use of CD7-RTX CAR T cells to treat a variety of malignancies expressing CD7. Future clinical trials are required to characterize the safety and efficacy of CD7-RTX CAR T cells.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1604490","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:33:34Z","timestamp":1754026414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report of non-gene editing CD7 CAR T cell therapy in CD7+ S\u00e9zary syndrome: preclinical validation and first-in-human use"],"prefix":"10.3389","volume":"16","author":[{"given":"Haichan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent M.","family":"DeStefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengxing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Waner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baozhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie Hsing-Ming","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yupo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221143025","article-title":"Current state of CAR-T therapy for T-cell Malignancies","volume":"13","author":"Luo","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/cancers15010094","article-title":"Adoptive cell therapy for T-cell Malignancies","volume":"15","author":"Fang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2584","article-title":"Cutaneous lymphomas-An update 2019","author":"Kempf","year":"2019","journal-title":"Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26299","article-title":"Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management","volume":"96","author":"Hristov","year":"2021","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1141108","article-title":"Mycosis fungoides and S\u00e9zary syndrome: clinical presentation, diagnosis, staging, and therapeutic management","volume":"13","author":"Miyashiro","year":"2023","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15526","article-title":"Epidemiology and prognostic factors for mycosis fungoides and S\u00e9zary syndrome in a multi-ethnic Asian cohort: a 12-year review","volume":"33","author":"Lim","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.043","article-title":"S\u00e9zary syndrome: a study of 176 patients at Mayo Clinic","volume":"67","author":"Kubica","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.3961","article-title":"Treatment of CD30-negative refractory mycosis fungoides with brentuximab vedotin","volume":"154","author":"Zhang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2018.11.02","article-title":"S\u00e9zary Syndrome, recent biomarkers and new drugs","volume":"8","author":"Cristofoletti","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.02.052","article-title":"Ultrahypofractionated low-dose total skin electron beam in advanced-stage mycosis fungoides and s\u00e9zary syndrome","volume":"117","author":"Elsayad","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1284045","article-title":"Advances in the treatment of mycoses fungoides and S\u00e9zary syndrome: a narrative update in skin-directed therapies and immune-based treatments","volume":"14","author":"Stuver","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.rpor.2013.07.009","article-title":"The current management of mycosis fungoides and S\u00e9zary syndrome and the role of radiotherapy: Principles and indications","volume":"19","author":"Mazzeo","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.8829.119","article-title":"An overview of cutaneous T cell lymphomas","volume":"5","author":"Bagherani","year":"2016","journal-title":"F1000Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124233","article-title":"Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma","volume":"4","author":"Vieyra-Garcia","year":"2019","journal-title":"JCI Insight"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/jha2.338","article-title":"Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice","volume":"3","author":"Sengsayadeth","year":"2022","journal-title":"EJHaem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric antigen receptors for T-cell Malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Review. Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7- specific CAR for the therapy of T-cell Malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21888","article-title":"S\u00e9zary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping","volume":"100","author":"Pulitzer","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/00000372-200202000-00002","article-title":"Low CD7 expression in benign and Malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue","volume":"24","author":"Murphy","year":"2002","journal-title":"Am J Dermatopathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.038","article-title":"Evaluation of immunophenotypic and molecular biomarkers for s\u00e9zary syndrome using standard operating procedures: A multicenter study of 59 patients","volume":"136","author":"Boonk","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of aggressive T cell lymphoblastic lymphoma\/leukemia using anti-CD5 CAR T cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-019-09937-9","article-title":"Characterization of an anti-CD5 directed CAR T-cell against T-cell Malignancies","volume":"16","author":"Wada","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell Malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.302","article-title":"A compound chimeric antigen receptor strategy for targeting multiple myeloma","volume":"32","author":"Chen","year":"2018","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-019-09948-6","article-title":"Targeting two antigens associated with B-ALL with CD19-CD123 compound car T cell therapy","volume":"16","author":"Yan","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149819","article-title":"CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy","volume":"6","author":"Kim","year":"2021","journal-title":"JCI Insight"},{"key":"B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell Malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.04.05820","article-title":"T-cell therapies for T-cell lymphoma","volume":"21","author":"Toner","year":"2019","journal-title":"Cytotherapy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1514729","article-title":"CD7-positive diffuse large B-cell lymphoma presenting as an intranasal tumor","volume":"2020","author":"Teshima","year":"2020","journal-title":"Case Rep Hematol"},{"key":"B34","first-page":"13","article-title":"T-cell\/Natural killer-cell neoplasms presenting as leukemia- Case series from single tertiary care center","volume":"10","author":"Naseem","year":"2016","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3390\/diagnostics13162629","article-title":"Update on the pathogenesis of enteropathy-associated T-cell lymphoma","volume":"13","author":"Abdullah","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104844","article-title":"Types of Tcell lymphoma-a cytogenetic perspective","volume":"84","author":"Samad","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2012.12.001","article-title":"Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study","volume":"45","author":"Malamut","year":"2013","journal-title":"Dig Liver Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-385559","article-title":"How I treat enteropathy-associated T-cell lymphoma","volume":"119","author":"Di Sabatino","year":"2012","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1019115","article-title":"CAR-T cell therapy for hematological Malignancies: Limitations and optimization strategies","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","article-title":"Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-019-09876-5","article-title":"Targeting T cell Malignancies using CD4CAR T-cells and implementing a natural safety switch","volume":"15","author":"Ma","year":"2019","journal-title":"Stem Cell Rev Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968336.17893.02","article-title":"P356: Phase 1\/2 dose-escalation study of anti-CD7 allogenic CAR-T cell in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (T-ALL\/LBL)","volume":"7","author":"Ghobadi","year":"2023","journal-title":"HemaSphere"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:33:35Z","timestamp":1754026415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2025.1604490"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1604490","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"1604490"}}